Totality of evidence in the development of ABP 215, an approved bevacizumab biosimilar
ABP 215 (MVASI™) is the first approved biosimilar to Avastin® (bevacizumab). It is approved in the USA and the European Union (EU) for all bevacizumab indications in these jurisdictions except for ovarian cancer in the USA due to orphan drug exclusivity. ABP 215 was shown to be structurally, functio...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
26 September 2019
|
| In: |
Immunotherapy
Year: 2019, Volume: 11, Issue: 15, Pages: 1337-1351 |
| ISSN: | 1750-7448 |
| DOI: | 10.2217/imt-2019-0125 |
| Online Access: | Verlag, Volltext: https://doi.org/10.2217/imt-2019-0125 Verlag, Volltext: https://www.futuremedicine.com/doi/10.2217/imt-2019-0125 
|
| Author Notes: | Michael Thomas, Nick Thatcher, Jerome Goldschmidt, Yuichiro Ohe, Helen J. McBride, Vladimir Hanes |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1689278730 | ||
| 003 | DE-627 | ||
| 005 | 20240404193230.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200205s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/imt-2019-0125 |2 doi | |
| 035 | |a (DE-627)1689278730 | ||
| 035 | |a (DE-599)KXP1689278730 | ||
| 035 | |a (OCoLC)1341303864 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Thomas, Michael |e VerfasserIn |0 (DE-588)1054438781 |0 (DE-627)79152213X |0 (DE-576)41027089X |4 aut | |
| 245 | 1 | 0 | |a Totality of evidence in the development of ABP 215, an approved bevacizumab biosimilar |c Michael Thomas, Nick Thatcher, Jerome Goldschmidt, Yuichiro Ohe, Helen J. McBride, Vladimir Hanes |
| 264 | 1 | |c 26 September 2019 | |
| 300 | |a 15 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 05.02.2020 | ||
| 520 | |a ABP 215 (MVASI™) is the first approved biosimilar to Avastin® (bevacizumab). It is approved in the USA and the European Union (EU) for all bevacizumab indications in these jurisdictions except for ovarian cancer in the USA due to orphan drug exclusivity. ABP 215 was shown to be structurally, functionally and clinically (pharmacokinetic, efficacy and safety) similar to the bevacizumab reference product; the pharmacokinetic study was conducted in healthy adult men (n = 202); safety and efficacy were evaluated in patients with advanced nonsquamous non-small-cell lung cancer (n = 642). Together, these results comprise the totality of evidence that provides scientific justification for extrapolation to all approved indications of the reference product and supports the clinical value of ABP 215 as an additional treatment option. | ||
| 700 | 1 | |a Thatcher, Nicholas |e VerfasserIn |0 (DE-588)1144315514 |0 (DE-627)1004522843 |0 (DE-576)495342858 |4 aut | |
| 700 | 1 | |a Goldschmidt, Jerome |e VerfasserIn |0 (DE-588)1204141525 |0 (DE-627)1689278056 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Immunotherapy |d London : Taylor & Francis, 2009 |g 11(2019), 15, Seite 1337-1351 |h Online-Ressource |w (DE-627)600591891 |w (DE-600)2495964-9 |w (DE-576)398101108 |x 1750-7448 |7 nnas |a Totality of evidence in the development of ABP 215, an approved bevacizumab biosimilar |
| 773 | 1 | 8 | |g volume:11 |g year:2019 |g number:15 |g pages:1337-1351 |g extent:15 |a Totality of evidence in the development of ABP 215, an approved bevacizumab biosimilar |
| 856 | 4 | 0 | |u https://doi.org/10.2217/imt-2019-0125 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://www.futuremedicine.com/doi/10.2217/imt-2019-0125 |x Verlag |x Resolving-System |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200205 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 1054438781 |a Thomas, Michael |m 1054438781:Thomas, Michael |d 910000 |d 950000 |d 950900 |e 910000PT1054438781 |e 950000PT1054438781 |e 950900PT1054438781 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 1 |x j | ||
| 999 | |a KXP-PPN1689278730 |e 3587803919 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"family":"Thomas","display":"Thomas, Michael","given":"Michael","role":"aut"},{"family":"Thatcher","display":"Thatcher, Nicholas","given":"Nicholas","role":"aut"},{"family":"Goldschmidt","display":"Goldschmidt, Jerome","given":"Jerome","role":"aut"}],"recId":"1689278730","relHost":[{"id":{"zdb":["2495964-9"],"eki":["600591891"],"issn":["1750-7448"]},"note":["Gesehen am 28.05.2024"],"title":[{"title":"Immunotherapy","title_sort":"Immunotherapy"}],"language":["eng"],"physDesc":[{"extent":"Online-Ressource"}],"recId":"600591891","type":{"media":"Online-Ressource","bibl":"periodical"},"pubHistory":["1.2009 -"],"part":{"volume":"11","text":"11(2019), 15, Seite 1337-1351","issue":"15","extent":"15","year":"2019","pages":"1337-1351"},"origin":[{"publisherPlace":"London ; London","dateIssuedKey":"2009","dateIssuedDisp":"2009-","publisher":"Taylor & Francis ; Future Medicine Ltd"}],"disp":"Totality of evidence in the development of ABP 215, an approved bevacizumab biosimilarImmunotherapy"}],"language":["eng"],"title":[{"title_sort":"Totality of evidence in the development of ABP 215, an approved bevacizumab biosimilar","title":"Totality of evidence in the development of ABP 215, an approved bevacizumab biosimilar"}],"note":["Gesehen am 05.02.2020"],"origin":[{"dateIssuedDisp":"26 September 2019","dateIssuedKey":"2019"}],"physDesc":[{"extent":"15 S."}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"name":{"displayForm":["Michael Thomas, Nick Thatcher, Jerome Goldschmidt, Yuichiro Ohe, Helen J. McBride, Vladimir Hanes"]},"id":{"doi":["10.2217/imt-2019-0125"],"eki":["1689278730"]}} | ||
| SRT | |a THOMASMICHTOTALITYOF2620 | ||